Monday, June 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Concerns raised over FDA plan to allow hearing aids with no prescription

The Food and Drug Administration (FDA) is proposing a rule to offer a new category of over-the-counter hearing aids in an attempt to boost accessibility and lower costs for the devices for Americans.

The agency announced its proposal that would allow certain hearing aids to be sold directly to the millions of adults who have “perceived mild to moderate” hearing loss, once it is finalized.

Under the updated rule, these patients could purchase specific air-conduction devices in stores or online without undergoing a medical exam or fitting. Adults with severe hearing loss or children with any hearing loss would still need a prescription.

Source: The Hill

https://thehill.com/homenews/administration/577365-fda-proposes-rule-to-offer-over-the-counter-hearing-aids

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!